Full Press Release Details
BridgeBio Pharma Grows Pipeline To 20+ Genetic Medicines With Four Assets Focused On Treating Genetically Driven Diseases At Their Source.
BBIO
BridgeBio Pharma Grows Pipeline To 20+ Genetic Medicines With Four Assets Focused On Treating Genetically Driven Diseases At Their Source
Key Takeaway: BridgeBio Pharma Grows Pipeline To 20+ Genetic Medicines With Four Assets Focused On Treating Genetically Driven Diseases At Their Source
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis